Outdoor High Performance) 8 18% 3 Growth in Asia / LATAM 6 3% 2 Other 100 19% 5 Sub-total $1,327 14% $146 Outdoor High Performance Impact (5) (3) Wage Inflation and Overtime (11) Other Supply Chain Costs (4) Synergies 5 Incentives, Other Employee Costs 8 FX (28) (5) Q1 2022 $1,294 11% $136 Q1 2022 SALES AND OPERATING INCOME ( T O TA L C O M PA N Y ) 6 Sales Growth Rate Adjusted Operating Income$ millions Adjusted EBITDA Q1 EBITDA BRIDGE 7 Price increases more than offset raw material and supply chain impacts Q1 2021 $ 161 Demand (23) $ millions CAI: Price / Mix 77 Inflation (54) SEM: Price / Mix 41 Inflation (26) Distribution: Price / Mix 84 Inflation (82) Net Price Benefit 40 Wage Inflation and Overtime (11) Other Supply Chain Costs (4) Synergies 5 Incentives, Other Employee Costs 8 FX (5) Q1 2022 $ 171    China Lockdowns / Russia Impact $ (7) Transportation (7) Outdoor High Performance (3) Q1 EPS BRIDGE 8 Q1 2021 - Adjusted EPS 0.89$ CAI 0.08 Specialty Engineered Materials 0.06 Distribution 0.00 Corporate Costs 0.02 F/X (0.04) Segment OI 0.12 Tax Rate (0.02) Q1 2022 - Adjusted EPS 0.99$ 10 15x stronger than steel Reduces weight by 30% vs. other solutions Well-maintained global asset base poised to serve growing demand • Purchase price of $1.48B represents 11.4x multiple of 2022 EBITDA • Acquisition will expand Avient’s composites and fiber portfolio with Dyneema®, the World’s Strongest Fiber™ • $415M sales and 30%+ EBITDA margins; Immediately accretive to pro forma 2022 EPS, adding $0.35 • 1,300 patents globally, ~50% of sales patent protected • 1,000+ employees across global production network and dedicated technology centers • Composites platform will increase from $261M to $680M in revenue and from $49M to $180M in EBITDA Indicates Dyneema ® location $175M (42%) $65M (16%) $175M (42%) 2022E Sales By Region ($M) (1) $0.35 EPS excludes intangible amortization (2) Based on 2022 expected results (1) (2) (2) F I T W I T H F O U R P I L L A R S T R AT E G Y 11 Specialization • Innovation-led organization with tremendous intellectual property value in trademarks, patents and “know-how” • Deep history of application development and premium, leading brand with the World’s Strongest FiberTM Globalization • Global customer base with an established presence across all major geographic regions • Global technology centers complement existing Composites applications and expertise Operational Excellence • Best-in-class safety performance • Well-run and maintained asset base fit to serve future growth • Highly effective and reliable supply chain with emphasis on optimizing service to customers Commercial Excellence • Deep customer relationships extend across the value chain and drive ability to grow • Offer a full suite of services with an active role in design, development and commercialization People Experienced and talented associates with a passion for safety, specialization and winning DY N E E M A ® OV E RV I E W K E Y I N D U S T R I E S PERSONAL PROTECTION Military • Law Enforcement • First Responders Body Armor • Helmets • Vehicle Protection $215M MARINE & SUSTAINABLE INFRASTRUCTURE Towing / Mooring • Aquaculture • Floating Wind • Offshore Cranes $130M CONSUMER Consumer • Outdoor High Performance • Safety Equipment $70M 12 Figures reflect 2022 expected sales MIFOverview Competition Value chain & Go-to-market Strategy Innovation Financials TECHNOLOGY 13 1,200 1,300 2,500 Avient Dyneema Combined Patents • True specialty business – the World’s Strongest Fiber™ • Deep history of application development with customers, strongest in the industry • The only UHMwPE (ultra-high molecular weight polyethylene) fiber producer that is backward integrated o Provides innovation advantage through control of all steps of the process • Complementary with our existing reinforced film expertise (PolyStrand) and engineered fiber presences (Fiber-Line) WINNING PROPERTIES Ultra high strength vs. weight Highly flexible Floats on water Chemically inert; no smell/taste and non-toxic High resistance to UV radiation Self-lubricating, with low friction One-of-a-kind technology ® FORMULATION PROCESS 14 • Like Avient, Dyneema® offers similar core competencies around formulation and material science • Technology that combines polymers and fibers to provide specialized, high performing solutions for customers • Design capabilities ensure that applications are highly customized for the specified end use DYNEEMA ® IN THE VALUE CHAIN 15 UHMwPE Fiber / Tapes Military Personnel, Law Enforcement Heavy Marine, Offshore Wind Energy and Mooring, Aquaculture Outdoor, Footwear, Apparel, Inflatables • Material Science • Formulation • Service INTERMEDIATE MANUFACTURING (CUSTOMERS) OEM / APPLICATION DEMAND TRENDS 16 • Military spending and near-term demand for higher performing personal protection products (like Dyneema®) expected to increase o European NATO members annual defense spend expected to increase by up to 20%(1) o Accelerated launch of next generation technology in North America • Policy-driven demand for sustainable energy; growth in floating offshore wind farms which require advanced, durable technology o Offshore wind expected to grow at a CAGR of 32% with the level of annual installations quadrupling over the next five years(2) • Continued investment in aquaculture as a sustainable food source(3) • Strong demand in outdoor high performance space across niche consumer applications aligns with 10% growth assumption for Avient’s Composites portfolio Sources: (1) “Funding NATO”, NATO.int (April 1, 2022) (2) “Global Wind Report 2021”, Global Wind Energy Council (3) “Aquaculture Supports a Sustainable Earth”, NOAA Fisheries 17 A L I G N M E N T W I T H S U S T A I N A B I L I T Y G O A L S P RO D U C T S AVIE NT ’S E XIS T ING COM P OS IT E S P ORT F OL IO D I V E R S E C A P A B I L I T I E S A N D S O L U T I O N S S E R V I N G M A N U F A C T U R E R S A N D O E M S LFT Tapes Laminates/Panels Shapes Pultrusion Engineered Fibers 18 AV I E N T ’ S C O M P O S I T E S P O RT F O L I O S A L E S A N D E B I T DA 19 $74 $84 $216 $212 $261 $5 $10 $32 $41 $49 $180 0 50 100 150 200 $- $50 $100 $150 $200 $250 $300 $350 $400 $450 $500 $550 $600 $650 $700 $750 2017 2018 2019 2020 2021 2022E $680 ($ in millions) • Dyneema® acquisition will further improve Composites EBITDA margins to 26% • Dyneema® will complement our existing portfolio with deep formulation expertise, innovative culture and global commercial presence • Composites will continue to be a key growth driver to deliver future revenue growth in excess of GDP (1) Pro forma for the acquisition of Dyneema® (1) D I S T R I BU T I O N D I V E S T I T U R E C O N S I D E R AT I O N S D I S T R I BU T I O N H I G H L I G H T S 21 $21 $57 $69 $94 $105 0 50 100 150 2006 2011 2016 2021 2022E • Leading North American Distribution business with longstanding blue-chip supplier and customer relationships • Commercial excellence and regulatory knowledge have grown healthcare portfolio to over 25% of sales and positioned business for long-term growth • Highly specialized portfolio of engineered polymers along with sustainable solution offerings • Leading digital capabilities through Avient Now, allowing enhanced visibility and 24/7 interface with customers • 98% free cash flow conversion drives greater than 30% after-tax return on invested capital (ROIC) • Potential divestiture allows us to remain modestly leveraged with net debt to adjusted EBITDA expected to be 2.9x and positions us for further specialty growth in the future EBITDA (in $M) DY N E E M A ® T R A N S AC T I O N OV E RV I E W 22 - $1.48B net purchase price - Represents 11.4x expected 2022 EBITDA - Committed financing in place - Permanent financing to be combination of available cash on-hand, new Senior Unsecured Notes, new Senior Secured Term Loan - Potential proceeds from Distribution divestment could be used to pay down near-term maturing debt - Closing expected in second half of 2022, subject to regulatory approvals and certain customary closing conditions Transaction Value Financing Closing Conditions / Timing C A P I TA L S T RU C T U R E / L E V E R AG E 23 • Financing commitments secured from Morgan Stanley and J.P. We also monitor earnings (defined as net income from continuing operations) before interest, taxes, depreciation and amortization (EBITDA) and adjusted EBITDA (EBITDA before the impact of special items) as a supplement to our GAAP measures. Three Months Ended March 31, 2022 Reconciliation to Condensed Consolidated Statements of Income GAAP Results Special Items Adjusted Results Operating Income $ 128.6 $ 7.8 $ 136.4 Income before income taxes $ 111.1 $ 7.7 $ 118.8 Income tax expense - GAAP (26.6) — (26.6) Income tax impact of special items — (2.0) (2.0) Tax adjustments — 1.5 1.5 Net income attributable to noncontrolling interests (0.3) — (0.3) Net income attributable to Avient shareholders $ 84.2 $ 7.2 $ 91.4 EPS $ 0.91 0.08 $ 0.99 Weighted-average diluted shares 92.3 92.3 92.3 1 Three Months Ended March 31, 2021 Reconciliation to Condensed Consolidated Statements of Income GAAP Results Special Items Adjusted Results Operating Income $ 120.4 $ 2.4 $ 122.8 Income before income taxes $ 102.6 $ 2.4 $ 105.0 Income tax expense - GAAP (22.9) — (22.9) Income tax impact of special items — (0.9) (0.9) Tax adjustments — 1.1 1.1 Net income attributable to noncontrolling interests (0.4) — (0.4) Net income attributable to Avient shareholders $ 79.3 $ 2.6 $ 81.9 EPS $ 0.86 0.03 $ 0.89 Weighted-average diluted shares 92.2 92.2 92.2 Year Ended December 31, 2021 Reconciliation to Condensed Consolidated Statements of Income GAAP Results Special Items Adjusted Results Operating income $ 381.2 $ 47.8 $ 429.0 Income from continuing operations before income taxes $ 304.6 $ 57.1 $ 361.7 Income tax expense - GAAP (74.0) — (74.0) Income tax impact of special items — (13.0) (13.0) Tax adjustments — 5.9 5.9 Net income attributable to noncontrolling interests 0.2 — 0.2 Net income from continuing operations attributable to Avient shareholders $ 230.8 $ 50.0 $ 280.8 EPS $ 2.51 0.54 $ 3.05 Weighted-average diluted shares 92.1 92.1 92.1 2 Reconciliation of EBITDA by Segment Three Months Ended March 31, Year Ended December 31, 2022 2021 2021 Operating income: Color, Additives and Inks $ 94.5 $ 88.8 $ 303.1 Specialty Engineered Materials 39.7 34.2 132.0 Distribution 24.2 24.0 93.2 Corporate and eliminations (29.8) (26.6) (147.1) Operating income $ 128.6 $ 120.4 $ 381.2 Items below OI in Corporate: Other income, net $ (0.6) $ 1.5 $ (1.3) Depreciation & amortization: Color, Additives and Inks $ 26.0 $ 27.4 $ 105.7 Specialty Engineered Materials 7.8 7.8 31.7 Distribution 0.2 0.2 0.8 Corporate and eliminations 3.8 1.7 7.7 Depreciation & Amortization $ 37.8 $ 37.1 $ 145.9 EBITDA: Color, Additives and Inks $ 120.5 $ 116.2 $ 408.8 Specialty Engineered Materials 47.5 42.0 163.7 Distribution 24.4 24.2 94.0 Corporate and eliminations (26.0) (24.9) (140.7) EBITDA $ 165.8 $ 159.0 $ 525.8 Reconciliation of Sales, Operating Income and EBITDA - Distribution Year Ended December 31, 2006 2011 2016 Sales $ 732.8 $ 996.5 $ 1,071.0 Operating income 19.2 56.0 68.2 Depreciation & amortization 1.5 0.7 0.7 EBITDA $ 20.7 $ 56.7 $ 68.9 3 Three Months Ended March 31, Year Ended December 31, Reconciliation to EBITDA and Adjusted EBITDA: 2022 2021 2021 Net income from continuing operations – GAAP $ 84.5 $ 79.7 $ 230.6 Income tax expense 26.6 22.9 74.0 Interest expense 16.9 19.3 75.3 Depreciation and amortization from continuing operations 37.8 37.1 145.9 EBITDA $ 165.8 $ 159.0 $ 525.8 Special items, before tax 7.7 2.4 57.1 Depreciation and amortization included in special items (2.1) (0.5) (1.7) Adjusted EBITDA $ 171.4 $ 160.9 $ 581.2 4 Masseto IR Presentation - Final.pdf Avient Corporation �specialty Portfolio Transformation Continues with Dyneema Acquisition DISCLAIMER Slide Number 3 Slide Number 4 Slide Number 5 Q1 2022 SALES AND OPERATING INCOME�(Total Company) Slide Number 7 Slide Number 8 Slide Number 9 Slide Number 10 FIT with Four Pillar Strategy Dyneema® overview Slide Number 13 Slide Number 14 Dyneema® in the Value Chain Demand trends Products Avient’s Existing Composites Portfolio Avient’s Composites Portfolio�Sales and Ebitda Distribution Divestiture Considerations Distribution highlights Dyneema® Transaction Overview Capital structure / Leverage Two-Year Leverage Goal Pro forma modeling Our Specialty Journey Acquisition History Clariant Color Acquisition Specialty Transformation 2022 ebitda margins vs. peers Culture and People Our Specialty Journey continues Slide Number 33 Avient Acquisition of Dyneema and Q1 2022 Results.pdf Masseto IR Presentation - 4.19 (515pm) - with attachments.pdf

We also monitor earnings (defined as net income from continuing operations) before interest, taxes, depreciation and amortization (EBITDA) and adjusted EBITDA (EBITDA before the impact of special items) as a supplement to our GAAP measures. Three Months Ended September 30, 2023 Three Months Ended September 30, 2022 Reconciliation to Condensed Consolidated Statements of Income: $ EPS $ EPS Net income (loss) from continuing operations attributable to Avient shareholders $ 5.1 $ 0.06 $ (27.4) $ (0.30) Special items, after tax 32.0 0.35 68.3 0.75 Amortization expense, after-tax 15.2 0.16 $ 13.4 $ 0.14 Adjusted net income / EPS $ 52.3 $ 0.57 $ 54.3 $ 0.59 Three Months Ended September 30, Reconciliation to EBITDA and Adjusted EBITDA: 2023 2022 Sales - GAAP $ 753.7 $ 823.3 Pro Forma APM adjustments — 60.7 Pro forma adjusted sales $ 753.7 $ 884.0 Net income from continuing operations – GAAP $ 5.1 $ (27.8) Income tax (benefit) expense (0.1) (1.2) Interest expense, net 30.3 37.3 Depreciation and amortization 46.4 39.8 EBITDA from continuing operations $ 81.7 $ 48.1 Special items, before tax 43.2 82.0 Interest expense included in special items (2.2) (10.0) Depreciation and amortization included in special items — (0.8) Adjusted EBITDA $ 122.7 $ 119.3 Pro forma APM adjustments — 17.2 Pro forma adjusted EBITDA $ 122.7 $ 136.5 Pro forma adjusted EBITDA as a % of sales 16.3 % 15.4 % 1 Year Ended December 31, Reconciliation to EBITDA and Adjusted EBITDA: 2006 2018 Sales $ 2,622.4 $ 3,533.4 Net income from continuing operations – GAAP $ 133.5 $ 160.8 Income tax expense 29.7 36.4 Interest expense, net 63.1 62.8 Depreciation and amortization 57.1 91.5 EBITDA from continuing operations $ 283.4 $ 351.5 Special items, before tax (34.0) 59.5 Depreciation and amortization included in special items — (3.0) JV - equity income (107.0) — Adjusted EBITDA $ 142.4 $ 408.0 Adjusted EBITDA as a % of sales 5.4 % 11.5 % Reconciliation to EBITDA and Adjusted EBITDA: Three Months Ended December 31, 2022 Net loss from continuing operations – GAAP $ (16.6) Income tax benefit (60.8) Interest expense, net 49.4 Depreciation and amortization 48.6 EBITDA from continuing operations $ 20.6 Special items, before tax 104.3 Interest expense included in special items (16.0) Depreciation and amortization included in special items (1.5) Adjusted EBITDA $ 107.4 Reconciliation of Pro Forma Adjusted Earnings per Share: Three Months Ended December 31, 2022 Net loss from continuing operations attributable to Avient shareholders $ (17.0) Special items, after tax 38.3 Amortization expense, after-tax 14.6 Adjusted net income from continuing operations excluding special items 35.9 Pro forma adjustments* 2.5 Pro forma adjusted net income from continuing operations attributable to Avient shareholders $ 38.4 Weighted average diluted shares 91.7 Pro forma adjusted EPS - excluding special items pro forma for APM acquisition $ 0.42 * Pro forma adjustment to reflect APM results for the period before Avient ownership including the impacts of debt financing and paydown of debt with net proceeds from the Distribution sale. 2 AVNT Q3 2023 Earnings Presentation Avient corporation�Third quarter 2023 results DISCLAIMER Slide Number 3 Avient protective materials �First Year Slide Number 5 Slide Number 6 Slide Number 7 Slide Number 8 Slide Number 9 Slide Number 10 Slide Number 11 Slide Number 12 Slide Number 13 Slide Number 14 Slide Number 15 Slide Number 16 Slide Number 17 Slide Number 18 Slide Number 19 Slide Number 20 Slide Number 21 IR Deck - AVNT-2023.09.30 Non GAAP Recs Attachment

Three Months Ended December 31, 2024 2023 Reconciliation to Condensed Consolidated Statements of Income $ EPS(1) $ EPS(1) Net income from continuing operations attributable to Avient shareholders $ 48.3 $ 0.52 $ 27.8 $ 0.30 Special items, after-tax (18.0) (0.20) 5.4 0.06 Amortization expense, after-tax 14.8 0.17 15.0 0.16 Adjusted net income / EPS $ 45.1 $ 0.49 $ 48.2 $ 0.52 (1) Per share amounts may not recalculate from figures presented herein due to rounding Year Ended December 31, 2024 2023 Reconciliation to Condensed Consolidated Statements of Income $ EPS(1) $ EPS(1) Net income from continuing operations attributable to Avient shareholders $ 169.5 $ 1.84 $ 75.8 $ 0.83 Special items, after-tax 15.9 0.17 79.3 0.86 Amortization expense, after-tax 59.5 0.65 61.5 0.67 Adjusted net income / EPS $ 244.9 $ 2.66 $ 216.6 $ 2.36 (1) Per share amounts may not recalculate from figures presented herein due to rounding Three Months Ended December 31, Year Ended December 31, Reconciliation to EBITDA and Adjusted EBITDA: 2024 2023 2024 2023 Net income from continuing operations – GAAP $ 48.5 $ 27.6 $ 170.7 $ 76.3 Income tax expense (benefit) 14.8 (7.0) 54.1 11.0 Interest expense 25.5 26.8 105.6 115.3 Depreciation and amortization from continuing operations 45.4 44.2 179.7 188.8 EBITDA from continuing operations $ 134.2 $ 91.6 $ 510.1 $ 391.4 Special items, before tax (23.9) 22.4 20.1 114.6 Interest expense included in special items — (0.1) (2.3) (2.3) Depreciation and amortization included in special items (0.3) — (1.5) (1.9) Adjusted EBITDA $ 110.0 $ 113.9 $ 526.4 $ 501.8 Adjusted EBITDA as a percent of sales 14.7 % 15.8 % 16.2 % 16.0 % 1 Three Months Ended December 31, Year Ended December 31, 2024 2023 2024 2023 Sales: Color, Additives and Inks $ 467.7 $ 459.4 $ 2,046.5 $ 2,007.4 Specialty Engineered Materials 279.7 259.8 1,196.8 1,138.2 Corporate (0.9) (0.2) (2.9) (2.8) Sales $ 746.5 $ 719.0 $ 3,240.4 $ 3,142.8 Gross margin: Color, Additives and Inks $ 152.6 $ 148.3 $ 681.1 $ 631.2 Specialty Engineered Materials 84.2 78.1 374.9 341.8 Corporate 22.7 (17.5) 0.7 (80.5) Gross margin $ 259.5 $ 208.9 $ 1,056.7 $ 892.5 Selling and administrative expense: Color, Additives and Inks $ 92.8 $ 86.5 $ 384.9 $ 371.3 Specialty Engineered Materials 49.6 48.7 207.7 199.3 Corporate 31.5 30.6 134.8 125.1 Selling and administrative expense $ 173.9 $ 165.8 $ 727.4 $ 695.7 Operating income: Color, Additives and Inks $ 59.8 $ 61.8 $ 296.2 $ 259.9 Specialty Engineered Materials 34.6 29.4 167.2 142.5 Corporate (8.8) (48.1) (134.1) (205.6) Operating income $ 85.6 $ 43.1 $ 329.3 $ 196.8 Depreciation and amortization: Color, Additives and Inks $ 21.9 $ 22.2 $ 87.5 $ 98.3 Specialty Engineered Materials 21.0 19.8 82.1 81.5 Corporate 2.5 2.2 10.1 9.0 Depreciation and amortization $ 45.4 $ 44.2 $ 179.7 $ 188.8 Earnings before interest, taxes, depreciation and amortization (EBITDA): Color, Additives and Inks $ 81.7 $ 84.0 $ 383.7 $ 358.2 Specialty Engineered Materials 55.6 49.2 249.3 224.0 Corporate (6.3) (45.9) (124.0) (196.6) Other income, net 3.2 4.3 1.1 5.8 EBITDA from continuing operations $ 134.2 $ 91.6 $ 510.1 $ 391.4 Special items, before tax (23.9) 22.4 20.1 114.6 Interest expense included in special items — (0.1) (2.3) (2.3) Depreciation and amortization included in special items (0.3) — (1.5) (1.9) Adjusted EBITDA $ 110.0 $ 113.9 $ 526.4 $ 501.8 2 Year Ended December 31, Adjusted Free Cash Flow Calculation 2024 2023 Cash provided by operating activities $ 256.8 $ 201.6 Taxes paid on gain on sale of business — 104.1 One-time payout associated with deferred compensation plans 20.8 — Adjusted cash provided by operating activities $ 277.6 $ 305.7 Capital expenditures (121.9) (119.4) Adjusted free cash flow $ 155.7 $ 186.3 Three Months Ended March 31, 2024 Reconciliation to Condensed Consolidated Statements of Income $ EPS(1) Net income from continuing operations attributable to Avient shareholders $ 49.4 $ 0.54 Special items, after-tax 5.5 0.06 Amortization expense, after-tax 14.9 0.16 Adjusted net income / EPS $ 69.8 $ 0.76 (1) Per share amounts may not recalculate from figures presented herein due to rounding 3 AVNT February Investor Presentation_2_25.pdf Avient Investor Presentation - February 2025_w_Non-GAAP.pdf Avient February 2025 Investor Presentation_w_non-GAAP.pdf Non-GAAP- IR Deck - AVNT-2024.12.31 2.06.25 12PM.pdf Attachment

KEY CHARACTERISTICS • Manufactured at four ISO 13485 certified sites, providing global consistency and increased security of supply • Documented change control beyond CAS number, reducing risk of change • Available as additive concentrates, ready-to-use additive formulations or ready-to-use additive/ colorant formulations for different polymers REGULATORY SUPPORT • Raw materials tested to: - ISO 10993-1 and USP biological evaluation - European Pharmacopeia 3.1.3/3.1.5 (polyolefin) - USP (polyethylene) - ICH Q3D elemental impurities • Registered Drug Master File (Type III) and/or Device Master File • Food contact established with FDA/EU* APPLICATION BULLETIN * FDA/EU compliance information available upon request; exceptions may occur Healthcare use limitations apply—see below.

KEY CHARACTERISTICS • Available for polyethylene, polypropylene, ABS, polycarbonate and styrenics • Bio-content of resin carrier varies from 70% to 100% depending on polymer—calculated to ASTM D6866 standard • Manufactured at four ISO 13485 certified sites, providing global consistency and security of supply • Documented change control beyond CAS number, reducing risk of change • Drop-in solutions that can be processed like fossil-based grades on common injection molding and extrusion machines • Can be provided as ready-to-use pre-colored or additive formulation REGULATORY SUPPORT • Raw materials tested to: - ISO 10993-1 - USP and (incl. class VI) - European Pharmacopeia, monograph 3.1.3/ 3.1.5 (polyolefin packaging materials) - USP (polyethylene) - Elemental impurities as per ICH Q3D • Registered Drug Master File (Type III) and/or Device Master File • Food contact according to US FDA and APPLICATION BULLETIN Sustainability Spotlight Bio-polymers Healthcare use limitations apply—see below.

MEVOPUR COLORANTS • Standard colors in PP and PE to shorten time-to-market • Custom colors matched to Pantone, RAL or other color reference • White colorants for pharmaceutical packaging for LDPE, HDPE and PP with opacity to reach USP chapter MEVOPUR FUNCTIONAL ADDITIVES • Antistatic formulation with good flow/impact for injection molding • Amide- and amine-free antistatic for film in contact with API (Active Pharmaceutical Ingredients) • UV blocking for transparent PP and PE packaging to meet USP chapter • Non-migrating friction reduction/processing aid for PE and PP • Laser marking/welding additive for fast, reliable marking/assembly • MVTR (Moisture Vapor Transmission Rate) reduction for HDPE to improve shelf-life • Thermal protection of the polymer during processing • Gamma/e-beam sterilization protection for PP (up to 50kGy) with color compensation for reduced yellowing REGULATORY SUPPORT • Raw materials tested to: - ISO 10993-1 and USP biological evaluation - European Pharmacopeia 3.1.3/3.1.5 (polyolefin) - USP (polyethylene) - ICH Q3D elemental impurities • Registered Drug Master File (Type III) and/or Device Master File • Food contact established with FDA/EU* APPLICATION BULLETIN * FDA/EU compliance information available upon request Bormed™ is a registered trademark of Borealis Healthcare use limitations apply—see below.

REGULATORY SUPPORT • Drug delivery devices • Pharmaceutical packaging • Medical equipment KEY CHARACTERISTICS • Manufactured at four ISO 13485 certified sites, providing global consistency and increased security of supply • Documented change control beyond CAS number level, reducing the risk of change • Allows crystallization in semi-crystalline polymers to begin faster and complete earlier REGULATORY SUPPORT • Raw materials tested to: - ISO 10993-1 and USP biological evaluation - European Pharmacopeia 3.1.3/3.1.5 (polyolefin) - USP (polyethylene) - ICH Q3D elemental impurities • Registered Drug Master File (Type III) and/or Device Master File • Food contact established with FDA/EU* APPLICATION BULLETIN * FDA/EU compliance information available upon request Healthcare use limitations apply—see below.

KEY CHARACTERISTICS • Formulated specifically for healthcare product applications • Wide portfolio of polymer additive solutions, including: - Antimicrobial technology - Surface energy modification, including low retention - Authentication technology - Lasermarking - Sterilization and content protection - Processing optimization - FDA compliant resin and color changeover solutions • OnCap HC Plus certified for USP Class VI and ISO 10993 bio-compatibility requirements; includes anti-oxidant, lasermarking, antimicrobial, radiopacifier, anti-stat, and polymer and gamma stabilization performance additives OnCap™ HC & OnCap™ HC Plus Additives for Healthcare PRODUCT BULLETIN INDUSTRY SUPPORT • Supported with a broad range of technical support and services: - Restricted medical-grade raw material selection process - Sampling program - World-class FDA cGMP manufacturing facilities - Batch traceability and formulation lockdown systems - FDA Drug Master Files or Medical Device Files maintenance MARKETS AND APPLICATIONS OnCap HC and OnCap HC Plus Additives are an excellent choice for medical devices and parts, pharmaceutical or cosmetic packaging, and many other healthcare related polymer applications.

Corporate seat Amsterdam First entry in Business Register 12-04-2006 Date of deed of incorporation 11-04-2006 Date of deed of last amendment to the Articles of Association 12-04-2021 Issued capital EUR 19.593,63 Paid-up capital EUR 19.593,63 Filing of the annual accounts The annual accounts for the financial year 2019 were filed on 01-07-2020.

TAXES Seller's invoices will include value added tax, where applicable, and such value added tax shall be a separate line item on the invoice. To the extent Products that have been sold exempt of value added tax and value added tax, due to a change in legislation or Governmental decree, shall be added to the sale price for said Products or new Products, Buyer shall be solely responsible for the payment of such value added tax. Seller shall not be liable to Buyer for any other taxes or duties of any kind unless specifically and mutually agreed to between the parties. 9.